tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Nicole Germino, 12 are a BUY (85.71%), 2 are a HOLD (14.29%).
Analyst Nicole Germino, currently employed at TRUIST, carries an average stock price target met ratio of 13.33% that have a potential upside of 12.99% achieved within 40 days.
Nicole Germino’s has documented 22 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SGMO, Sangamo Therapeutics at 07-Nov-2023.
Analyst best performing recommendations are on PNT (POINT BIOPHARMA GLOBAL).
The best stock recommendation documented was for PNT (POINT BIOPHARMA GLOBAL) at 11/15/2022. The price target of $14 was fulfilled within 388 days with a profit of $7.89 (129.13%) receiving and performance score of 3.33.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
1 months 24 days ago
(24-Sep-2024)
3/4 (75%)
$5.52 (44.23%)
188
Hold
$35
$18.86 (116.85%)
$84
1 months 28 days ago
(20-Sep-2024)
2/8 (25%)
$15.57 (80.13%)
51
Buy
$24
$7.86 (48.70%)
2 years 24 days ago
(24-Oct-2022)
0/2 (0%)
$4.8 (25.00%)
Buy
$12
$-1.72 (-12.54%)
$15
2 years 7 months 16 days ago
(01-Apr-2022)
2/2 (100%)
$-12.72 (-51.46%)
502
Buy
$168
$151.86 (940.89%)
$168
3 years 2 months 14 days ago
(03-Sep-2021)
1/5 (20%)
$128.88 (329.45%)
57
What Year was the first public recommendation made by Nicole Germino?
